RxDoctor Payments Data

Jeremy Stidham, MD

Internal Medicine · Cullman, ALNPI 1285821397

Payments from drug & device makers

$5,331in general payments, 2019–2025

Across 335 payments — averaging $15.91 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Pfizer$821
  • Novo Nordisk$605
  • AbbVie$463
  • Axsome Therapeutics, Inc.$317
  • Astellas Pharma US Inc$267
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$263
  • plus $3K from 43 others

What the payments were for

  • Food & beverage$5,29899%
  • Education$341%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$5,331 in reported general payments places this provider in the 85th percentile of 1,533 internal medicine providers in Alabama.

See all internal medicine providers in Alabama

Medicare billing

Part B allowed, 2024
$280,832
Medicare patients
564
Services billed
8,871

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban377$291,923
OzempicSemaglutide171$193,869
MounjaroTirzepatide164$193,348
FarxigaDapagliflozin Propanediol167$151,516
TrulicityDulaglutide139$141,441
JardianceEmpagliflozin133$119,111
XareltoRivaroxaban104$85,111
Trelegy ElliptaFluticasone/Umeclidin/Vilanter94$73,138
JanuviaSitagliptin Phosphate62$59,374
MyrbetriqMirabegron58$39,901
LinzessLinaclotide59$38,811
TrintellixVortioxetine Hydrobromide63$35,589
Dexlansoprazole DrDexlansoprazole108$32,623
InvokanaCanagliflozin29$31,881
Esomeprazole Magnesium269$26,903

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$80$334,789303 claims
PfizerEliquis$821$291,923377 claims
Novo NordiskOzempic, Rybelsus$605$217,864187 claims
AstraZenecaFarxiga$136$151,516167 claims
Boehringer IngelheimJardiance, Tradjenta, Spiriva Respimat$92$142,867162 claims
Johnson & JohnsonXarelto, Invokana$245$116,992133 claims
MerckJanuvia, Janumet, Belsomra, Janumet Xr$25$108,790144 claims
GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta$134$98,710145 claims
Astellas Pharma US IncMyrbetriq$267$39,90158 claims
AbbVieLinzess$463$38,81159 claims
Takeda Pharmaceuticals U.S.A., Inc.Trintellix$114$35,58963 claims
Sanofi-aventis U.S. LLCSoliqua 100-33$102$19,40818 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,533 internal medicine providers in Alabama.

Other internal medicine in Cullman

See the full list for Alabama

Where these figures come from

Is this you, or does something look wrong? →